Natural History and Prognostic Factors of Advanced Cholangiocarcinoma without Surgery, Chemotherapy, or Radiotherapy: A Large-Scale Observational Study
2
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Background/Aims: We aimed to evaluate survival time and prognostic factors in patients with advanced unresectable cholangiocarcinoma who have not received surgery, chemotherapy, or radiotherapy. Methods: A total of 1,377 patients, who were diagnosed with primary cholangiocarcinoma between 1996 and 2002, were reviewed retrospectively according to the following inclusion criteria: histologically proven primary adenocarcinoma arising from the bile-duct epithelium, advanced unresectable stages, no severe comorbidity that can affect survival time, and no history of surgery, chemotherapy, or radiotherapy. Results: Of the 1,377 cases reviewed, 330 patients complied with the inclusion criteria and were thus eligible to participate in this study; 203 had intrahepatic cholangiocarcinoma and 127 had hilar cholangiocarcinoma. The overall survival time of the entire cohort (n=330) was median 3.9 months (range; 0.2 to 67.1). The survival time was significantly shorter in the intrahepatic cholangiocarcinoma group (3.0±5.3 months) than in the hilar cholangiocarcinoma group (5.9±10.1 months; Kaplan-Meier survival analysis). Multivariate analysis revealed that distant metastasis was a poor prognostic factor for intrahepatic cholangiocarcinoma (p＜ 0.001), baseline serum albumin ＞3.0 g/dL was a favorable prognostic factor (p=0.02), and baseline serum carcinoembryonic antigen level ＞30 ng/mL was a poor prognostic factor for hilar cholangiocarcinoma (p=0.01). Conclusions: The median survival of advanced unresectable cholangiocarcinoma is dismal.
Abstract
Background/Aims: We aimed to evaluate survival time and prognostic factors in patients with advanced unresectable cholangiocarcinoma who have not received surgery, chemotherapy, or radiotherapy. Methods: A total of 1,377 patients, who were diagnosed with primary cholangiocarcinoma between 1996 and 2002, were reviewed retrospectively according to the following inclusion criteria: histologically proven primary adenocarcinoma arising from the bile-duct epithelium, advanced unresectable stages, no severe comorbidity that can affect survival time, and no history of surgery, chemotherapy, or radiotherapy. Results: Of the 1,377 cases reviewed, 330 patients complied with the inclusion criteria and were thus eligible to participate in this study; 203 had intrahepatic cholangiocarcinoma and 127 had hilar cholangiocarcinoma. The overall survival time of the entire cohort (n=330) was median 3.9 months (range; 0.2 to 67.1). The survival time was significantly shorter in the intrahepatic cholangiocarcinoma group (3.0±5.3 months) than in the hilar cholangiocarcinoma group (5.9±10.1 months; Kaplan-Meier survival analysis). Multivariate analysis revealed that distant metastasis was a poor prognostic factor for intrahepatic cholangiocarcinoma (p＜ 0.001), baseline serum albumin ＞3.0 g/dL was a favorable prognostic factor (p=0.02), and baseline serum carcinoembryonic antigen level ＞30 ng/mL was a poor prognostic factor for hilar cholangiocarcinoma (p=0.01). Conclusions: The median survival of advanced unresectable cholangiocarcinoma is dismal.
참고문헌 (41)
- de Groen PC, "Biliary tract cancers", N Engl J Med, 341, pp.1369~1378 (1999)
- Lazaridis KN, "Cholangiocarcinoma", Gastroenterology, 128, pp.1655~1667 (2005)
- Nair S, "Mortality from hepatocellular and biliary cancers: changing epidemiological trends", Am J Gastroenterol, 97, pp.167~171 (2002)
- Patel T, "Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States", Hepatology, 33, pp.1353~1357 (2001)
- Olnes MJ, "A review and update on cholangiocarcinoma", Oncology, 66, pp.167~179 (2004)
- Jarnagin WR, "Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma", Ann Surg, 234, pp.507~517 (2001)
- Witzigmann H, "Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to r1", r2 resection, 2006, pp.244, 230~239
- Sasaki A, "Intrahepatic peripheral cholangiocarcinoma: mode of spread and choice of surgical treatment", Br J Surg, 85, pp.1206~1209 (1998)
- Nakeeb A, "Cholangiocarcinoma: a spectrum of intrahepatic, perihilar, and distal tumors", Ann Surg, 224, pp.463~473 (1996)
- Washburn WK, "Aggressive surgical resection for cholangiocarcinoma", Arch Surg, 130, pp.270~276 (1995)
- Patel T, "Cholangiocarcinoma: emerging approaches to a challenging cancer", Curr Opin Gastroenterol, 23, pp.317~323 (2007)
- Reddy SB, "Current approaches to the diagnosis and treatment of cholangiocarcinoma", Curr Gastroenterol Rep, 8, pp.30~37 (2006)
- Mansfield SD, "Management of hilar cholangiocarcinoma in the North of England: pathology, treatment, and outcome", World J Gastroenterol, 11, pp.7625~7630 (2005)
- Ortner ME, "Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study", Gastroenterology, 125, pp.1355~1363 (2003)
- Lee HY, "Preoperative assessment of resectability of hepatic hilar cholangiocarcinoma: combined CT and cholangiography with revised criteria", Radiology, 239, pp.113~121 (2006)
- Weber SM, "Staging laparoscopy in patients with extrahepatic biliary carcinoma: analysis of 100 patients", Ann Surg, 235, pp.392~399 (2002)
- Burke EC, "Hilar cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system", Ann Surg, 228, pp.385~394 (1998)
- D'Angelica MI, "Resectable hilar cholangiocarcinoma: surgical treatment and long-term outcome", Surg Today, 34, pp.885~890 (2004)
- Isaji S, "Clinicopathological features and outcome of hepatic resection for intrahepatic cholangiocarcinoma in Japan", J Hepatobiliary Pancreat Surg, 6, pp.108~116 (1999)
- Sano T, "Macroscopic classification and preoperative diagnosis of intrahepatic cholangiocarcinoma in Japan", J Hepatobiliary Pancreat Surg, 6, pp.101~107 (1999)
- Bismuth H, "Resection or palliation: priority of surgery in the treatment of hilar cancer", World J Surg, 12, pp.39~47 (1988)
- Smith AC, "Randomised trial of endoscopic stenting versus surgical bypass in malignant low bileduct obstruction", Lancet, 344, pp.1655~1660 (1994)
- Miyakawa S, "Results from the Biliary Tract Cancer Statistics Registry in Japan based on general rules for surgical and pathological studies on cancer of the biliary tract: hilar cholangiocarcinoma", Kan Tan Sui, 50, pp.415~424 (2005)
- Connor S, "Palliation for suspected unresectable hilar cholangiocarcinoma", Eur J Surg Oncol, 33, pp.341~345 (2007)
- Shaib YH, "Endoscopic and surgical therapy for intrahepatic cholangiocarcinoma in the united states: a population-based study", J Clin Gastroenterol, 41, pp.911~917 (2007)
- Paik WH, "Palliative treatment with self-expandable metallic stents in patients with advanced type III or IV hilar cholangiocarcinoma: a percutaneous versus endoscopic approach", Gastrointest Endosc, 69, pp.55~62 (2009)
- Broome U, "Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis", Gut, 38, pp.610~615 (1996)
- Kaplan GG, "The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis", Am J Gastroenterol, 102, pp.1042~1049 (2007)
- Weber A, "Long-term outcome and prognostic factors of patients with hilar cholangiocarcinoma", World J Gastroenterol, 13, pp.1422~1426 (2007)
- Su CH, "Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma", Ann Surg, 223, pp.384~394 (1996)
- Su WC, "A clinical study of 130 patients with biliary tract cancers and periampullary tumors", Oncology, 53, pp.488~493 (1996)
- Kuusela P, "Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases", Br J Cancer, 63, pp.636~640 (1991)
- Gores GJ, "Early detection and treatment of cholangiocarcinoma", Liver Transpl, 6, pp.S30~34 (2000)
- Charatcharoenwitthaya P, "Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis", Hepatology, 48, pp.1106~1117 (2008)
- Kim HJ, "A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve", Am J Gastroenterol, 94, pp.1941~1946 (1999)
- Miwa S, "Predictive factors for intrahepatic cholangiocarcinoma recurrence in the liver following surgery", J Gastroenterol, 41, pp.893~900 (2006)
- Heimbach JK, "Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma", Transplantation, 82, pp.1703~1707 (2006)
- Ohtsuka M, "Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival", Br J Surg, 89, pp.1525~1531 (2002)
- Ghazale A, "Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy", Gastroenterology, 134, pp.706~715 (2008)
- Kim MH, "Primary intrahepatic stones", Am J Gastroenterol, 90, pp.540~548 (1995)
- Cha JM, "Clinicopathological review of 61 patients with early bile duct cancer", Clin Oncol, 18, pp.669~677 (2006)